Google Halts UK YouTube TV Measurement Service After Legal Action 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
CANTON, Mass., May 23, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in June:
- The Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th at 9:00 a.m. ET in New York City
- The 37th Annual William Blair Growth Stock Conference on Wednesday, June 14th at 2:40 p.m. CT at The Four Seasons Hotel Chicago
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alex Dasalla [email protected]
